mannoside Degradation Pathway (G4123)

Target Name: MAN2C1

NCBI ID: G4123

MAN2C1

mannoside Degradation Pathway

MAN2C1 (Alpha-D-mannoside mannohydrolase) is a protein that is expressed in various cell types of the human body, including neurons, muscle cells, and red blood cells. It is a key enzyme in the degradation of mannosides, which are a type of sugar found in many plants and animals, including humans. Mannosides are often used as potential drug targets or biomarkers due to their unique structure and the role they play in various cellular processes.

The mannoside pathway is a complex series of biochemical reactions that involve the breakdown of mannosides into simpler sugars, which can then be utilized by cells for energy or other cellular processes. The first step in this pathway is the degradation of alpha-mannoside by MAN2C1, which converts the alpha-mannoside to beta-mannoside. This conversion is critical for the further degradation of mannosides into simpler sugars that can be utilized by cells.

MAN2C1 is a member of the glycoside hydrolase family 16 (GH16) and is classified as a proton pump. It is a monomer that has four distinct subunits, each of which has a unique function in the mannoside degradation pathway. The subunits are named based on their subunit number, with the N-terminus being the most abundant and the C-terminus being the least abundant.

The alpha-mannoside mannohydrolase enzyme is a critical player in the mannoside degradation pathway. It is responsible for converting the alpha-mannoside to beta-mannoside, which is then converted to simple sugars that can be utilized by cells. The rate of this conversion is regulated by various factors, including the concentration of alpha-mannoside, the availability of oxygen, and the presence of other nutrients or substances in the environment.

In addition to its role in mannoside degradation, MAN2C1 has also been shown to play a critical role in the regulation of cellular processes. For example, it has been shown to be involved in the regulation of cell adhesion, migration, and the formation of tight junctions. It has also been shown to play a role in the regulation of the immune response and the production of antibodies.

The potential use of MAN2C1 as a drug target or biomarker is due to its unique structure and the various cellular processes that it is involved in. The alpha-mannoside mannohydrolase enzyme has a distinct subunit composition, which makes it a unique target for drug discovery. Additionally, the fact that it is involved in multiple cellular processes makes it a promising biomarker for a variety of diseases.

In conclusion, MAN2C1 (Alpha-D-mannoside mannohydrolase) is a critical enzyme involved in the degradation of mannosides, which are a type of sugar found in many plants and animals. Its unique structure and the various cellular processes that it is involved in make it a potential drug target or biomarker. Further research is needed to fully understand the role of MAN2C1 in cellular processes and its potential as a drug or biomarker.

Protein Name: Mannosidase Alpha Class 2C Member 1

Functions: Cleaves alpha 1,2-, alpha 1,3-, and alpha 1,6-linked mannose residues on cytoplasmatic free oligosaccharides generated by N-glycoprotein degradation pathways

The "MAN2C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAN2C1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets